Two structurally modified compounds derived from an anti-inflammatory metabolite demonstrated enhanced anti-inflammatory ...

The recommendations surround important updates to standard criteria that are commonly used despite being decades old.

Crohn’s and Colitis Canada’s Grants-in-Aid of Research Program supports investigator-driven research with defined objectives that advance understanding of Crohn’s disease, ulcerative colitis and ...

Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn’s diseaseThree ...

Click here for the previous article↓ Nothing particularly eventful happened during my hospitalization. My usual attending physician came to check on me and said we would try a new medication after ...

Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative ...

Two medical experts called by the defense testified Monday in the trial of Heather and Brian Allen, challenging parts of the ...

Montai has dosed the first participants in a Phase 1 trial of MTAI-1025, a novel oral NRF2 agonist for the treatment of ulcerative colitis.

For millions of Americans living with inflammatory bowel disease, a stomachache or sudden trip to the bathroom can be much ...

Inflammatory bowel disease is not exclusively a human affliction. Dogs, cats, and livestock all suffer from chronic colitis-like syndromes marked by persistent diarrhoea, weight loss, abdominal ...

Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for ...

Phase 3 ABTECT-Maintenance will report 44-week efficacy and safety of obefazimod in moderately to severely active UC using a randomized, double-blind, placebo-controlled design. Subset analyses will ...